Editas Medicine Announces Third Quarter 2017 Results and Update – GuruFocus.com
Simply Wall St |
Editas Medicine Announces Third Quarter 2017 Results and Update
GuruFocus.com … disease and beta thalassemia. In data to be presented at ASH, we will demonstrate high levels of gene disruption of adult human hematopoietic stem cells with CRISPR/Cpf1 and efficient targeted integration at the beta-hemoglobin locus with CRISPR/Cas9. Head to Head Survey: Editas Medicine (EDIT) and The Competition 7 Breakout Stocks for 2018 |
